Call
Epirubicin PhaRes IV Injection contains Epirubicin Hydrochloride
Epirubicin PhaRes IV Injection uses for
Epirubicin Injection is an anthracycline topoisomerase II inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer
Acute leukaemias; Lymphoma; Multiple myeloma; Solid tumours:
- As a single agent: 600 mg/m2 3 wkly.
- Max (total cumulative dose): 0.9 g/m2.
- Palliative care: 12.55 mg/m2 once wkly.
Adjuvant treatment in axillary-node positive breast cancer: Recommended starting doses: 10020 mg/m2 as a single dose on day 1 or as 2 divided doses on days 1 and 8 of each 28-day cycle. Repeat for 6 cycles.
Intravesical Local treatment of bladder carcinoma: As 0.1% soln: 50 mg/wk for 8 wk; reduce dose if chemical cystitis develops.
For carcinoma in-situ: 80 mg in 50 mL wkly.
For prevention of recurrence in patients who have undergone transurethral resection: 50 mg/wk for 4 wk, followed by 50 mg/mth for 11 mth; retain soln in the bladder for 1 hr during each administration.
Read more here Epirubicin PhaRes
Talk Doctor Online in Bissoy App